Key Highlights

  • Revenue reached USD 275.4 million in the third quarter of 2026 against USD 216.8 million a year earlier, a rise of about 27% (calculated from the two reported figures).
  • Net income was USD 15.3 million for the quarter, down from USD 24.3 million, while the nine-month figure swung to income of USD 14.1 million from a USD 150.0 million loss.
  • Clinical cases tested rose to 61,500 in the quarter from 50,800, and to 173,500 for nine months from 146,700, according to the quarterly report.
  • Cash, restricted cash and marketable securities totaled USD 769.2 million on September 30, 2026, against USD 400.0 million of principal outstanding under the term loan.

Revenue Climbs but Quarterly Profit Slips

Caris Life Sciences (NASDAQ:CAI) filed its Quarterly Report on November 4, 2026, covering the period ended September 30. Revenue of USD 275.4 million compared with USD 216.8 million, and Net Income was USD 15.3 million versus USD 24.3 million. Nine-month revenue was USD 755.2 million against USD 519.1 million, about 45% higher (calculated). The nine-month result moved to net income of USD 14.1 million from a net loss of USD 150.0 million. The extract reviewed does not itemize why quarterly profit declined while sales grew, so the drivers are not stated here, and no guidance or consensus comparison appears in the material.

Case Volume and New Tests Behind the Growth

The company describes itself as a TechBio Business that uses molecular data and AI to support cancer care, with tests run on more than 1,200,000 cases as of September 30, 2026. Clinical cases rose about 21% in the quarter (calculated), to 61,500. In the second quarter of 2026 it launched Caris Detect, a multi-cancer early detection blood test, plus Caris ChromoSeq for blood cancers and Caris MI Clarity. The filing names biopharma partners including Moderna, AbbVie, Xencor, Merck KGaA and Genentech. Revenue is split between molecular profiling services and pharma Research and Development services, and the company says it expects higher testing volumes and a wider test menu to support growth in 2026 and beyond.

Reimbursement, Capacity and the Balance Sheet

The report lists payer coverage as a central risk for Caris Life Sciences (NASDAQ:CAI), because average selling prices and gross margins depend on what insurers agree to reimburse. Scaling laboratory capacity, billing and quality systems for new tests is another, and the company says commercial success of its early detection tests requires further validation studies. Operating Cash Flow was USD 39.1 million for nine months versus USD 38.4 million, which is nearly flat despite the much higher revenue. Liquidity of USD 769.2 million sits against a term Loan with USD 400.0 million of principal outstanding.

Where Things Stand

Sales growth was strong, but the quarterly profit did not follow. Caris Life Sciences (NASDAQ:CAI) grew revenue by about 27% and case volume by about 21% (both calculated), yet net income fell to USD 15.3 million from USD 24.3 million, and the extract does not explain the gap. The nine-month swing to profit and USD 769.2 million of liquidity are the stronger signals. Next markers to watch are adoption of Caris Detect and Caris ChromoSeq, payer coverage decisions and how nine-month cash flow of USD 39.1 million evolves as volumes expand.